Abstract: DNA encoding triol polyketide synthase (TPKS) has been isolated, purified and sequenced. Expression vectors comprising TPKS, cells transformed with the expression vectors, and processes employing the transformed cells are provided.
Type:
Grant
Filed:
May 25, 1995
Date of Patent:
April 28, 1998
Assignee:
Merck & Co., Inc.
Inventors:
Victor A. Vinci, Michael J. Conder, Phyllis C. McAda, Christopher D. Reeves, John Rambosek, Charles Ray Davis, Lee E. Hendrickson
Abstract: The present invention describes the production of interferon-.tau. proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-.tau. protein are also described. In one aspect, the invention includes ovine interferon-.tau.. In another aspect the invention includes multiple forms of human interferon-.tau..
Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
Type:
Grant
Filed:
February 4, 1994
Date of Patent:
April 14, 1998
Assignee:
G. D. Searle & Co.
Inventors:
S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
Type:
Grant
Filed:
December 2, 1996
Date of Patent:
April 7, 1998
Inventors:
Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier
Abstract: The invention relates to a family of substantially pure, receptor like TGF-.beta.1 binding glycoproteins. These molecules are characterized by molecular masses of 160 kd, 70-80 kd, and 30-40 kd as determined by SDS-PAGE, and the ability to bind the TGF-.beta.1 molecule. This family of molecules is useful in identifying and/or quantifying TGF-.beta.1 in a sample, as well as inhibiting its effect on cells. Also described are nucleic acid sequences which code for the protein monomer making up the molecules.
Abstract: The chemotactic protein CP-10, in essentially pure form, having an apparent molecular weight of approximately 10 kD and having chemotactic activity for neutrophils, monocytes/macrophages and/or other mammalian cells, or an analogue, mutant, fragment, derivative or functional homologue of CP-10. Amino acid and nucleotide sequences for CP-10 are disclosed, as well as production and use thereof.
Type:
Grant
Filed:
April 23, 1993
Date of Patent:
March 24, 1998
Assignee:
The Heart Research Institute Ltd.
Inventors:
Carolyn Geczy, Richard John Simpson, Martin Lackmann
Abstract: The present invention relates generally to identification of proteins, designated TIH proteins, that interact with casein kinase I isoforms and to isolation of polynucleotides encoding the same.
Abstract: The present invention describes a mutant human tissue factor protein which binds functional Factor VII/VIIa but is substantially free of functional procoagulant cofactor activity, and compositions containing the mutant protein. Also disclosed are methods for using the mutant human tissue factor proteins, and recombinant DNA vectors for expressing the protein.
Abstract: The present invention relates, in general, to a method of enhancing the production performance of avians, by administering to a bird a heterologous protein comprised of inhibin protein, or a fragment thereof, and a carrier protein. The present invention also relates to a method of enhancing the production performance of avians, by administering to a bird a fusion gene product comprising a gene encoded for the expression of alpha-subunit avian inhibin protein, or a fragment thereof, and a gene encoded for the expression of a carrier protein. An effective amount of the heterologous protein or fusion gene product is administered to an animal such that an immunological response occurs in the animal against the heterologous protein. The present invention further relates to the above heterologous protein and fusion gene product, and to methods of producing the same.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
March 10, 1998
Assignees:
Agritech Technologies, Ltd., Board of Supervisors of Louisiana State Univ. and Agricultural & Mechanical College
Inventors:
William C. Fioretti, Konstantin Kousoulas, Daniel G. Satterlee
Abstract: The present invention relates to novel receptor polypeptides, which, upon interaction with certain ligands, or activation by certain compounds, modulate transcription of certain genes by binding to cognate response elements associated with promoters of such genes. The novel receptors of the invention modulate transcription in the presence of retinoid compounds. The receptors of the present invention differ significantly from known retinoic acid receptors, in protein primary sequence and in responsiveness to exposure to various retinoids. The invention provides DNAs encoding the novel receptors, expression vectors for expression of the receptors, cells transformed with such expression vectors, cells co-transformed with such expression vectors and with reporter vectors to monitor modulation of transcription by the receptors, and methods of using such co-transformed cells in screening for compounds which are capable, directly or indirectly, of activating the receptors.
Type:
Grant
Filed:
November 8, 1994
Date of Patent:
March 3, 1998
Assignee:
The Salk Institute for Biological Studies
Abstract: A drug for preventing and curing liver diseases comprising at least one member selected from interleukin-1 and its derivatives as an effective component. The drug meaningfully suppresses GOT and GPT activities in blood which are markers of liver diseases, and also suppresses symptoms such as choloplania.
Abstract: The present invention provides novel assay methods for identifying compounds that may have both estrogen agonist and antagonist properties. In particular, the assay use cells comprising promoters having an AP1 site linked to a reporter gene. Compounds capable of inducing or blocking expression of the reporter gene can thus be identified. The compounds may be further tested for the ability to modulate the standard estrogen response, as well.
Type:
Grant
Filed:
March 27, 1995
Date of Patent:
March 3, 1998
Assignee:
The Regents of the University of California
Inventors:
Peter Kushner, Paul Webb, Renee Williard, C. Anthony Hunt, Gabriella Lopez
Abstract: This invention provides a novel purified TGF-.beta.-binding glycoprotein, endoglin, an isolated nucleic acid molecule that encodes an amino acid sequence corresponding to the TGF-.beta.-binding glycoprotein, soluble endoglin-derived polypeptide, and fragments thereof. A pharmaceutical composition which comprises the endoglin-derived polypeptide purified by applicants or produced by applicants' recombinant methods and a pharmaceutically acceptable carrier is further provided as well as methods of treating patients which comprise administering to the patient the pharmaceutical composition of this invention.
Type:
Grant
Filed:
June 2, 1995
Date of Patent:
February 17, 1998
Assignee:
HSC Research & Development Limited Partnership
Inventors:
Michelle Letarte, Joan Massague, Carmelo Bernabeu, Sela Cheifetz
Abstract: A synthetic plasmid in which DNA encoding protein of a feline interferon is integrated, a transformant obtainable by the transformation of a host cell by the use of the synthetic plasmid and a feline interferon having a biological activity given by a protein carrying a specific amino acid sequence, a feline interferon gene encoding the feline interferon, a feline interferon precursor comprised of a cleavable peptide or a signal peptide being linked to the N terminal of the feline interferon, a feline interferon precursor gene encoding the feline interferon precursor and a method for producing the feline interferon, which are applied to the mass production of a feline interferon to be used as a remedy for feline viral disease and tumor.
Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.
Abstract: Chimeric polypeptides encoded by a DNA sequence having a first DNA subsequence coding for a fragment of at least one of the .alpha.-and/or .beta.-chain of the human interleukin-5 receptor, and a second DNA subsequence coding for the constant domains of a heavy--or a light-chain of a human immunoglobulin, or a fragment thereof are useful in treating illnesses with demonstrated eosinophilia.
Type:
Grant
Filed:
April 13, 1995
Date of Patent:
January 27, 1998
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Rene Devos, Walter Fiers, Jose van der Heyden, Geert Plaetinck, Jan Tavernier
Abstract: Methods and vectors for expressing interferon-alpha (IFN-.alpha.) proteins in E. coli are provided. Use of a vector comprising an IFN-.alpha. sequence fused to an E. coli heat-stable enterotoxin signal sequence (STII) under the control of the E. coli phosphatase (phoA) promoter affords high levels of correctly-folded and -processed, biologically active IFN-.alpha. polypeptides.
Type:
Grant
Filed:
May 26, 1994
Date of Patent:
January 20, 1998
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Rudolf Hauptmann, Edgar Falkner, Gerhard Bodo, Tilman Voss, Ingrid Maurer-Fogy
Abstract: Novel human chemokine receptors, MCP-1RA and MCP-1RB, and processes for producing them are disclosed. The receptors, which are alternately spliced versions of MCP-1 receptor protein may be used in an assay to identify antagonists of MCP-1 which are therapeutically useful in the treatment of atherosclerosis and other diseases characterized by monocytic infiltrates.
Abstract: The present invention describes the production of interferon-.tau. proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-.tau. protein are also described. In one aspect, the invention includes ovine interferon-.tau.. In another aspect the invention includes multiple forms of human interferon-.tau..